Study on Vimseltinib and Oral Contraceptives
This study is looking for healthy women, aged 18 to 55, to understand how a drug called vimseltinib affects combined oral contraceptives (birth control pills containing ethinyl estradiol and levonorgestrel). Researchers want to see if vimseltinib changes how much of the birth control medication stays in your body and for how long. This is measured by looking at the maximum drug concentration (Cmax) and the total amount of drug in your system over time (AUC). The study will last about 35 days. The current status of this study is unclear, but it plans to enroll 24 participants.
- Study design
- This interventional study plans to enroll 24 healthy female participants. The phase of the study is not specified.
- What's involved
- You would take vimseltinib and a combined oral contraceptive. The study will last approximately 35 days.
- Compensation
- Not stated in the trial record.
- Follow-up
- Blood samples for drug levels will be taken from before you take the drugs up to 72 hours after the last dose.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Clinical Team · STUDY_DIRECTOR · Deciphera Pharmaceuticals, LLC
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Pharmacokinetics (PK): Maximum Observed Plasma Drug Concentration (Cmax) of EE and LNGPredose up to 72 Hours Post Dose
- PK: Area Under the Plasma Concentration-Time Curve from Time 0 up to Time t (AUC0-t), Where t is the Last Time Point at which the Concentration is Above the Lower Limit of Quantification, of EE and LNGPredose up to 72 Hours Post Dose
- PK: AUC from Time 0 to Infinity (AUC0-∞) of EE and LNGPredose up to 72 Hours Post Dose